Five different profiles of dihydropyridines in blocking T-type Ca2+ channel subtypes (Cav3.1 (α1G), Cav3.2 (α1H), and Cav3.3 (α1I)) expressed in Xenopus oocytes

European Journal of Pharmacology

Volumn 613, Issue 1-3, 2009, Pages 100-107

  Furukawa, Taiji ^a   Nukada, Toshihide ^b   Namiki, Yoshiko ^b   Miyashita, Yoriko ^a,b   Hatsuno, Kento ^a   Ueno, Yasunari ^a   Yamakawa, Takeshi ^a   Isshiki, Takaaki ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Calcium antagonist; Dihydoropyridine; T type calcium channel; Xenopus oocyte

Indexed keywords

AMLODIPINE; ARANIDIPINE; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL; CALCIUM CHANNEL CAV3.1; CALCIUM CHANNEL CAV3.2; CALCIUM CHANNEL CAV3.3; CILNIDIPINE; DIHYDROPYRIDINE DERIVATIVE; EFONIDIPINE; FELODIPINE; MANIDIPINE; MEPIRODIPINE; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NILVADIPINE; NIMODIPINE; NITRENDIPINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOPUS;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; MEMBRANE POTENTIALS; OOCYTES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS;

EID: 65749088895     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.036     Document Type: Article

References (31)

1. Akaike N., Kanaide H., Kuga T., Nakamura M., Sadoshima J., and Tomoike H. Low-voltage-activated calcium current in rat aorta smooth muscle cells in primary culture. J. Physiol. 416 (1989) 141-160
2. Akaike N., Kostyuk P.G., and Osipchuk Y.V. Dihydropyridine-sensitive low-threshold calcium channels in isolated rat hypothalamic neurones. J. Physiol. 412 (1989) 181-195
3. Akaike N., Kostyuk P.G., and Osipchuk Y.V. Dihydropyridine-sensitive low-threshold calcium channels in isolated rat hypothalamic neurones. J. Physiol. 412 (1989) 181-195
4. Formenti A., Arrigoni E., and Mancia M. Low-voltage activated calcium channels are differently affected by nimodipine. Neuroreport 5 (1993) 145-147
5. Furukawa T., Yamakawa T., Midera T., Sagawa T., Mori Y., and Nukada T. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 291 (1999) 464-473
6. Furukawa T., Miura R., Honda M., Kamiya N., Mori Y., Takeshita S., Isshiki T., and Nukada T. Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels. Br. J. Pharmacol. 143 (2004) 1050-1057
7. Furukawa T., Nukada T., Miura R., Ooga K., Honda M., Watanabe S., Koganesawa S., and Isshiki T. Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes. J. Cardiovasc. Pharmacol. 45 (2005) 241-246
8. Heady T.N., Gomora J.C., Macdonald T.L., and Perez-Reyes E. Molecular pharmacology of T-type Ca2+ channels. Jpn. J. Pharmacol. 85 (2001) 339-350
9. Hermsmeyer K., Mishra S., Miyagawa K., and Minshall R. Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists. Clin. Ther. 19 Suppl A (1997) 18-26
10. Horiba M., Muto T., Ueda N., Opthof T., Miwa K., Hojo M., Lee J.K., Kamiya K., Kodama I., and Yasui K. T-type Ca(2+) channel blockers prevent cardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca(2+) channel blockers. Life Sci. 82 (2008) 554-560
11. Kaneda M., and Akaike N. The low-threshold Ca current in isolated amygdaloid neurons in the rat. Brain Res. 497 (1989) 187-190
12. Koschak A., Reimer D., Huber I., Grabner M., Glossmann H., Engel J., and Striessnig J. alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol. Chem. 276 (2001) 22,100-22,106
13. Kostyuk P.G., and Shirokov R.E. Deactivation kinetics of different components of calcium inward current in the membrane of mice sensory neurones. J. Physiol. 409 (1989) 343-355
14. Krayenbuhl J.C., Vozeh S., Kondo-Oestreicher M., and Dayer P. Drug-drug interactions of new active substances: mibefradil example. Eur. J. Clin. Pharmacol. 55 (1999) 559-565
15. Kumar P.P., Stotz S.C., Paramashivappa R., Beedle A.M., Zamponi G.W., and Rao A.S. Synthesis and evaluation of a new class of nifedipine analogs with T-type calcium channel blocking activity. Mol. Pharmacol. 61 (2002) 649-658
16. Lipscombe D., Pan J.Q., and Gray A.C. Functional diversity in neuronal voltage-gated calcium channels by alternative splicing of Ca(v)alpha1. Mol. Neurobiol. 26 (2002) 21-44
17. Lory P., and Chemin J. Towards the discovery of novel T-type calcium channel blockers. Expert Opin. Ther. Targets 11 (2007) 717-722
18. Martin R.L., Lee J.H., Cribbs L.L., Perez-Reyes E., and Hanck D.A. Mibefradil block of cloned T-type calcium channels. J. Pharmacol. Exp. Ther. 295 (2000) 302-308
19. Nilius B., Talavera K., and Verkhratsky A. T-type calcium channels: the never ending story. Cell. Calcium. 40 (2006) 81-88
20. Okayama S., Imagawa K., Naya N., Iwama H., Somekawa S., Kawata H., Horii M., Nakajima T., Uemura S., and Saito Y. Blocking T-type Ca2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens. Res. 29 (2006) 493-497
21. Ozawa Y., Hayashi K., Nagahama T., Fujiwara K., and Saruta T. Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydronephrotic kidney. Hypertension 38 (2001) 343-347
22. Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol. Rev. 83 (2003) 117-161
23. Perez-Reyes E., Van Deusen A.L., and Vitko I. Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol. Exp. Ther. 328 (2008) 621-627
24. Romanin C., Seydl K., Glossmann H., and Schindler H. The dihydropyridine niguldipine inhibits T-type Ca(2+) currents in atrial myocytes. Pflugers. Arch. 420 (1992) 410-412
25. Shin J.B., Martinez-Salgado C., Heppenstall P.A., and Lewin G.R. A T-type calcium channel required for normal function of a mammalian mechanoreceptor. Nat. Neurosci. 6 (2003) 724-730
26. Sugano N., Wakino S., Kanda T., Tatematsu S., Homma K., Yoshioka K., Hasegawa K., Hara Y., Suetsugu Y., Yoshizawa T., Utsunomiya Y., Tokudome G., Hosoya T., Saruta T., and Hayashi K. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int. 73 (2008) 826-834
27. Takahashi K., and Akaike N. Calcium antagonist effects on low-threshold (T-type) calcium current in rat isolated hippocampal CA1 pyramidal neurons. J. Pharmacol. Exp. Ther. 256 (1991) 169-175
28. Talley E.M., Cribbs L.L., Lee J.H., Daud A., Perez-Reyes E., and Bayliss D.A. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J. Neurosci. 19 (1999) 1895-1911
29. Van der Vring J.A., Cleophas T.J., Van der Wall E.E., and Niemeyer M.G. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group. Am. J. Ther. 6 (1999) 229-233
30. Wada Y., Yamashita T., Imai K., Miura R., Takao K., Nishi M., Takeshima H., Asano T., Morishita R., Nishizawa K., Kokubun S., and Nukada T. A region of the sulfonylurea receptor critical for a modulation of ATP-sensitive K+ channels by G-protein bg-subunits. EMBO J. 19 (2000) 4915-4925
31. Yunker A.M. Modulation and pharmacology of low voltage-activated ("T-type") calcium channels. J. Bioenerg. Biomembr. 35 (2003) 577-598